Corbus Pharmaceuticals Stock Surges on Positive Phase 1 Obesity Drug Data

Corbus Pharmaceuticals (NASDAQ: CRBP) shares surged Tuesday after the company announced positive topline data from a Phase 1 clinical trial of its experimental obesity drug, CRB-913. The early-stage results showed the drug was well-tolerated and led to a statistically significant reduction in body weight compared to a placebo.

Trial Shows Promising Weight Loss

The clinical-stage biopharmaceutical company reported that its drug, a next-generation NPY1R inverse agonist, met its primary safety and tolerability objectives. The single-dose escalation study was conducted in healthy obese participants.

Key findings from the trial data released by Corbus include:

• A placebo-adjusted mean body weight reduction of 2.9 kg (6.4 lbs) at Day 29.
• The drug was reported to be well-tolerated, with no serious adverse events observed.
• Pharmacokinetic data from the study supports a potential once-daily oral dosing regimen.

Ad

Market Reaction and Context

Investors reacted favorably to the early proof-of-concept data, sending shares of Corbus Pharmaceuticals sharply higher in morning trading on the Nasdaq. The positive results are notable as CRB-913 utilizes a different mechanism of action than the popular GLP-1 agonists that currently dominate the lucrative weight-loss drug market.

Next Steps

Corbus stated that based on these encouraging results, it plans to advance the program into a multiple-dose Phase 1b study. The company expects to initiate this next phase of the trial in the second half of 2024, which will further evaluate the drug's impact on body weight over a longer treatment period.